As a biopharma CMO, Symbiosis Pharmaceutical Services was established in 2011 in response to increasing global demand for niche, sterile manufacturing specialists that could satisfy product supply needs for clinical trials.
We created our purpose-built biologics facility in Stirling, Scotland, specifically designed with small molecule production capabilities in mind to support biotech and speciality biopharmaceutical companies worldwide that require small-scale injectable products.
Differing from most biopharma CMOs, from the day our operations commenced we offered rapid access to manufacturing slots and quick release of drug products to ensure tight timelines are successfully met. Naturally, this has been a real hit with our clients.
Our core manufacturing capability takes place within an MHRA-licensed facility, which enables our team to fill bulk volumes under 100 litres, including products that require aseptic liquid filling and lyophilisation, such as:
- Biologics including mAb’s, proteins, peptides and RNA
- Cytotoxic, cytostatic and high potent APIs including ADCs
- Small molecules
Regulatory compliance, technical capability and operational flexibility are core to Symbiosis’ offerings and direct access to the best people who deliver projects on time is what our clients demand and receive every day.
Read more about our company philosophy here.
Since the company began, we have steadily grown with our sustainable business model. Our team, facilities and capabilities have continued to expand in-line with growing demands from clients in Europe and North America.
If you’re interested in what we do and how we do it, please contact us today. If you would like to work for Symbiosis, check our careers page for the latest vacancies.